Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESBRIET vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pirfenidone inhibits TGF-β stimulated collagen production and reduces fibroblast proliferation, exhibiting anti-inflammatory and antifibrotic effects in pulmonary fibrosis.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Idiopathic pulmonary fibrosis (IPF)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
801 mg three times daily orally with food.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is approximately 3 hours (range 1.5-5 hours) in healthy adults. In patients with idiopathic pulmonary fibrosis, half-life is similar but exhibits interindividual variability.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Primarily hepatic via CYP1A2 (major), with minor contributions from CYP2C9, CYP2C19, CYP2D6, and CYP2E1.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal excretion of parent drug and metabolites accounts for approximately 99% of elimination, with about 82% recovered in urine and 1% in feces. Pirfenidone is extensively metabolized, with less than 1% excreted unchanged.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Protein binding is approximately 50-58%, primarily to albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Volume of distribution is approximately 1.0 L/kg, indicating extensive tissue distribution.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral bioavailability is approximately 80% (range 70-90%) under fed conditions; food reduces peak concentration but increases total exposure.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR 30-50 m L/min: 267 mg three times daily; GFR < 30 m L/min: not recommended.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh A: 801 mg three times daily; Child-Pugh B: 267 mg three times daily; Child-Pugh C: contraindicated.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Not established; safety and efficacy in pediatric patients have not been studied.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
No specific dose adjustment recommended; monitor renal function and consider lower starting dose due to age-related decline in renal function.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Hepatotoxicity: monitor liver function tests before and during treatment; discontinue if significant elevation.,Photosensitivity and rash: avoid sun exposure; use sunscreen.,Gastrointestinal effects: nausea, diarrhea, dyspepsia; take with food.,Elevated liver enzymes: dose reduction or interruption may be required.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Severe hepatic impairment (Child-Pugh Class C),Severe renal impairment requiring dialysis,History of hypersensitivity to pirfenidone or any excipient
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Take with meals to reduce GI intolerance. Grapefruit and grapefruit juice may increase pirfenidone blood levels and should be avoided. Avoid smoking as it induces CYP1A2 and may reduce drug efficacy.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Pirfenidone is teratogenic in animal studies, causing fetal malformations and embryotoxicity at clinically relevant exposures. There are no adequate human studies. Use during pregnancy is contraindicated; effective contraception is required before and during treatment. First trimester carries the highest risk for major congenital anomalies; second and third trimester risks include fetal growth restriction and potential pulmonary toxicity.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
No human data on milk excretion; animal studies show drug and metabolites present in breast milk. Unknown M/P ratio. Risk of infant toxicity cannot be excluded. Breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No established dosing guidelines for pregnancy. Significant pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Theoretical adjustments are not recommended due to unknown safety; therapy should be discontinued if pregnancy occurs. If continuation is deemed unavoidable, dose individualization based on therapeutic drug monitoring is suggested but unvalidated.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Pirfenidone (Esbriet) is an antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). It reduces decline in lung function but does not reverse fibrosis. Monitor liver function tests (LFTs) monthly for 6 months then every 3 months due to risk of hepatotoxicity. Photosensitivity is common; advise strict sun avoidance and broad-spectrum sunscreen. Dosage titration over 14 days reduces GI side effects. Avoid use with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) as they increase pirfenidone exposure.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Take with food to reduce nausea and upset stomach.,Avoid sun exposure; wear protective clothing and apply sunscreen daily due to risk of severe sunburn.,Do not stop or change dose without consulting your doctor; taper is not required but missed doses should be skipped.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, fatigue, or abdominal pain.,Avoid smoking and grapefruit products as they may affect drug levels.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
No interactions on record
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESBRIET vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
ESBRIET is a Antifibrotic that works by Pirfenidone inhibits TGF-β stimulated collagen production and reduces fibroblast proliferation, exhibiting anti-inflammatory and antifibrotic effects in pulmonary fibrosis.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESBRIET and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESBRIET is: 801 mg three times daily orally with food.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESBRIET and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESBRIET is classified as Category C. Pirfenidone is teratogenic in animal studies, causing fetal malformations and embryotoxicity at clinically relevant exposures. There are no adequate human studies. Use during pregn. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.